LGD-4033
Also known as: Ligandrol
Status
No approved product. No FDA-approved labeling exists. LGD-4033 is not an approved medicine, and the FDA has issued public warnings and warning letters covering the sale of selective androgen receptor modulators in body-building products, citing liver injury and cardiovascular risk.
What it is
A SARM studied in early trials for lean mass, with clear suppression.
What published research measured
The best-studied compound in this category in humans, which is a low bar but a real distinction. A placebo-controlled phase 1 trial in healthy young men (Basaria and colleagues, 2013) reported dose-dependent gains in lean body mass over three weeks. The same trial documented what the marketing omits: dose-dependent suppression of total testosterone, free testosterone, sex hormone binding globulin, follicle stimulating hormone and high-density lipoprotein cholesterol, with testosterone still not fully recovered at the end of follow-up. Later trials in postmenopausal women and in men with cancer cachexia have been published. Case reports of drug-induced liver injury with cholestatic and hepatocellular patterns have accumulated in the literature. Prohibited at all times in sport under WADA class S1.2.
Source
Basaria et al. 2013, Journals of Gerontology — phase 1 trial in healthy young men · FDA public warnings and warning letters on SARMs in body-building products
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.